AZN Astrazeneca Plc

12,106.00

-20.00 (-0.16%)

19 Jul 2024 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Astrazeneca Plc	LSE:AZN	London	Ordinary Share	GB0009895292	ORD SHS $0.25

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-20.00	-0.16%	12,106.00	12,120.00	12,122.00	12,190.00	12,024.00	12,080.00	999,558	16:35:02

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
Pharmaceutical Preparations	45.81B	5.96B	3.8415	31.55	187.98B

New Patient Satisfaction Study With budesonide/formoterol Combination Therapy and fluticasone/salmeterol Combination Therapy in

20/05/2008 1:15pm

PR Newswire (US)

Astrazeneca (LSE:AZN)
Historical Stock Chart

From Jul 2019 to Jul 2024

WILMINGTON, Del., May 20 /PRNewswire-FirstCall/ -- A new open-label study evaluated patient satisfaction with budesonide/formoterol combination therapy and fluticasone/salmeterol combination therapy, as measured by the Asthma Treatment Satisfaction Measure (ATSM)(1). Patients participating in the study were ages 18 years and older with moderate to severe asthma(1) and had been previously treated with inhaled corticosteroids(1). Results were presented today at the International Conference of the American Thoracic Society held in Toronto, May 16-21, 2008. Results showed that patients receiving budesonide/formoterol combination therapy administered as adjustable dosage reported significantly greater satisfaction on the ATSM overall (p=0.02) than patients receiving fluticasone/salmeterol combination therapy, especially in the categories of feel medication begins to work (p